Given the growing role of NRF2 as therapeutic target in FRDA and in several chronic diseases [2,3], we evaluated the effect of six redox compounds on NRF2 expression in order to design a potential drugs classification. This evidence concerns the gene NFE2L2 and Friedreich ataxia.